Seroquel Switching Study: Feasibility of Switching any Antipsychotic Treatment to Seroquel in Patients with Schizophrenia

Study identifier:D1444C00147

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients with Schizophrenia

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

No

Study drug

Seroquel SR

Sex

All

Actual Enrollment

550

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2004
Primary Completion Date: -
Study Completion Date: 01 May 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria